argenx to Acquire Unnatural Products in Deal Valued at Up to $1.15 Billion to Advance AI-Driven Drug Discovery
Biopharmaceutical company argenx has agreed to acquire Unnatural Products, a technology company specializing in platforms for discovering and designing drug compounds, in a transaction valued at up to $1.15 billion, according to Reuters.
The deal highlights the growing investment appeal of artificial intelligence-powered biotechnology and the pharmaceutical industry's shift toward using machine learning, advanced chemistry and computational technologies to identify potential treatments.
Rather than relying exclusively on conventional research and development methods, pharmaceutical companies are increasingly adopting digital tools to explore new therapeutic compounds and address biological targets that have been difficult to reach through traditional drug development.
AI platform focuses on macrocyclic peptide discovery
Unnatural Products' core technology is built around the discovery and design of macrocyclic peptides, a class of chemical compounds considered promising for developing treatments that target proteins and biological mechanisms that conventional drugs may struggle to access.
Its platform combines artificial intelligence and machine learning with advanced chemistry tools to accelerate compound design and improve drug properties.
This approach could support the development of innovative therapies, including the possibility of producing certain compounds as oral medicines rather than injectable treatments.
Acquisition includes upfront and milestone-based payments
The transaction includes an initial cash payment of $550 million, alongside potential additional payments of up to $595 million.
The extra consideration will depend on the achievement of specified milestones related to product development and regulatory progress, bringing the potential total deal value to $1.15 billion.
Unnatural Products is expected to retain its workforce and headquarters in Santa Cruz, California, where it will operate as a dedicated peptide discovery and development center within argenx's research organization.
Pharmaceutical companies expand investments in AI technology
The acquisition reflects a broader strategy among global drugmakers to secure advanced technology platforms through acquisitions of specialized startups, rather than focusing solely on established medicines or existing manufacturing operations.
Data, algorithms and computing capabilities are becoming increasingly important in shortening drug discovery and development timelines and expanding the range of biological targets that researchers can pursue.
The deal also demonstrates the growing convergence of artificial intelligence and biotechnology, as digital technologies move beyond medical data analysis into the design of molecules and pharmaceutical compounds, creating new opportunities for innovation and investment in the drug industry.
